Other papers submitted by: Dr Christopher Cannon

open access to scientific and medical research

News:

Expressions of interest for Editor-in-Chief - the International Medical Case Reports Journal Read more

Back to User profile » Dr Christopher Cannon

Paper published by Dr Christopher Cannon:

Review

Noteworthy Comment: The biology and current status of CETP inhibition as a therapeutic target are authoritatively presented in this re-evaluation. Anacetrapib, a potent CETP inhibitor, may prove to be a valuable addition to the clinician's armamentarium.

Highly-accessed

Anacetrapib: potential for the prevention and treatment of coronary heart disease

Steen DL, Khera AV, Cannon CP

Research Reports in Clinical Cardiology 2013, 4:39-53

Published Date: 4 April 2013